Log In
BCIQ
Print this Print this
 

AP102 (formerly G02113)

  Manage Alerts
Collapse Summary General Information
Company Amryt Pharma plc
DescriptionNovel anti-tumour somatostatin analogue (SSA) peptide
Molecular Target Somatostatin receptor 2 (SSTR2) ; Somatostatin receptor 5 (SSTR5)
Mechanism of Action 
Therapeutic ModalityPeptide

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$42.5M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/19/2016

$42.5M

0

0

Get a free BioCentury trial today